2024-10-09 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets innovative medicines for serious illnesses.

**Performance Analysis:**

1. **Relative Performance:** AMGN has underperformed the S&P 500 (VOO) in the past, with a cumulative return of 78.76% compared to VOO's 133.14%. This results in a current relative underperformance of -54.38%. While this indicates underperformance, the relative performance has improved compared to its historical range, which has seen a maximum divergence of 7.29% and a minimum of -79.13%. Currently, AMGN is positioned at 31.65% of its historical relative performance range.

2. **Recent Price Action:** AMGN's recent price action shows a slight downtrend with the following key levels:
    * **Closing Price:** 319.66
    * **5-day Moving Average:** 319.88
    * **20-day Moving Average:** 327.44
    * **60-day Moving Average:** 328.38
    
3. **Technical Indicators:**
    * **RSI (Relative Strength Index):** 37.08 - This indicates that the stock is currently in oversold territory, potentially suggesting a bounce back.
    * **PPO (Percentage Price Oscillator):** -0.43 - A negative PPO value suggests that the stock price is below its 12-period moving average and the momentum is declining. 
    * **Delta_Previous_Relative_Divergence:** -13.26 - A negative value implies a short-term downtrend in relative price movement.
    * **Expected Return:** 0.0 - This means that the estimated 5-year return, relative to the S&P 500, is currently expected to be flat. 

4. **Recent Earnings & Outlook:**
    | Date        | EPS  | Revenue        |
    |-------------|------|----------------|
    | 2024-08-07 | 1.39 | 8.39 B$        |
    | 2024-05-03 | -0.21| 7.45 B$        |
    | 2023-10-31 | 3.23 | 6.90 B$        |
    | 2023-08-04 | 2.58 | 6.99 B$        |
    | 2024-08-07 | 2.58 | 6.99 B$        |

AMGN's latest earnings report (2024-08-07) shows an EPS of 1.39, beating estimates. The revenue also exceeded expectations, coming in at 8.39 B$. This positive result suggests that the company is performing well despite the broader market's volatility.

5. **News & Recent Issues:**
    * **Recent Market Outlook:** While the stock is currently in oversold territory, the market outlook for AMGN is positive.  Analysts cite its strong product pipeline, including a potential new treatment for Alzheimer's Disease, as a key driver for future growth. 
    * **Analyst Opinions:** Many analysts remain bullish on AMGN, with several issuing "buy" ratings. They believe the company's strong financial position, diverse product portfolio, and commitment to innovation will continue to drive future performance. 
    * **Performance Highlights:** AMGN continues to benefit from strong demand for its core products, particularly in the biosimilars segment. The company is also investing heavily in research and development to expand its product offerings.

**Overall Analysis:**

While AMGN has underperformed the S&P 500 in the past, recent earnings results and positive analyst sentiment suggest that the stock could be poised for a rebound. Technical indicators also indicate a potential short-term bounce. However, it is important to note that the current market environment is volatile, and investors should consider their individual risk tolerance before investing in AMGN. 

**Conclusion:** 

Despite past underperformance, AMGN's strong fundamentals, promising product pipeline, and positive analyst outlook make it a potential investment opportunity. However, careful consideration of the current market volatility and your own investment strategy is crucial before making any investment decisions. 
